Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Merck & Co (MRK) and Procter & Gamble (PG) are lower despite beating earnings expectations after lowering their guidance ...

Julie Hyman provides an overview of the top stories of the trading day in just 60 seconds on Yahoo Finance's Market Minute. Merck & Company (MRK) warns investors that it expects a $200 million hit ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...